Verndari is developing a proprietary formulation and delivery technology that will allow the company to create unique new vaccines. These new vaccines will serve large and profitable markets.

The Verndari proprietary technology is designed to

  • Enable pain-free delivery of vaccines.
  • Enable low cost delivery of vaccines.
  • Enable room-temperature stable vaccines.
  • Enable rapid response to changes in influenza as well as other infectious agents.

Verndai’s proprietary MicroArray Patch or MAP design and automated MicroArray Patch Manufacturing System or MAP MS will allow Verndari to dramatically change the delivered cost of vaccines, thus having a significant impact on healthcare globally.

Verndari MAPs have been created to achieve two imperatives.  First, when activated they must deliver a precise amount of sterile vaccine to the dermal layer.  Second, they must be capable of being produced by the millions in a ready-to-use configuration. 

We combine three technologies to achieve this outcome.  We use photochemical etching to form MAPs and shape the individual tips.  We use microfluidic dispensing to deliver a precise amount of vaccine into each individual tip.  Finally, we use integrated robotic assembly to deliver prepackaged MAPs.  Each sealed MAP packet will contain a ready-to-use miniapplicator in sterile packaging.

Our raw material is a very thin sheet of 304 stainless steel.  We use photochemical etching to create fixed planar arrays (x y axis) of individual MAPs.  Each individual tip is precisely formed and remains connected to the SS304 sheet by a pre-formed trough.  The MAPs are formed with a sharp point and chiseled edges, and each has a pre-formed well designed to subsequently receive the appropriate vaccine.

A state-of-the-art microfluidic dispensing instrument is used to deliver a precise amount of vaccine into each pre-formed well.  This microfluidic dispensing equipment is capable of simultaneously and accurately applying the fluid into hundreds of wells outlined on the stainless-steel sheet, leaving each well filled with five to ten Nano liters of vaccine.  This small amount of vaccine dries immediately and adheres to the well of the MAPs.

Figure 1a shows a 5 x 5 -1 MicroArray with 5 nL of 1% Congo Red dispensed into the well of our microtips.   This shows the accuracy and precision of the dispensing process.  Figure 1b shows a MicroArray currently in fabrication moving to a circular “happy face” format.   This format has found favor with the managers of focus groups sponsored by PATH for use in global childhood vaccine programs.   The idea is to make vaccination fun and enjoyable by creating a “tatoo happy face” that disappears after a few hours at the site of vaccine administation.

Figure 1a and 1b.  5 x 5 -1 microarray and a happy face array.

Figure 1a and 1b.  5 x 5 -1 microarray and a happy face array.

Our integrated robotic assembly manufacturing approach applies pressure to the preformed trough, mechanically brings each loaded tip to vertical, and delivers the individual MAPs for singulation and packaging operations.  The output of the line is pre-packaged sterile Verndari MAPs.  These sealed packages are oxygen and moisture free and ready for immediate use. 

All three technologies currently exist at the scale and accuracy we need.  It will require focus to integrate these technologies, but all are proven in current large scale manufacturing operations.

Vaccine Vision

A broad family of room temperature stable vaccines self administered via a painless patch...

read more
Featured Article
Featured Team Member

John H. Brown

John graduated with High Honors from Princeton in 1968 and received a Harvard MBA in 1970. He was Co-Head of Hamblet and Hayes from 1971 to 1980, when H&H was sold to CIBA-Geigy. During the next seventeen years John was with CIBA-Geigy (now renamed to Novartis), rising to become a Senior Vice President. During that period, he held many different positions including head of various points of Finance, Strategy, Business Development, Licensing, Policy, State and Federal Government Affairs, Pharmacoeconomics Research, QC/QA, Safety, Health, and Environment, and Regulatory Compliance. He also oversaw the over the counter business, CIBA-Corning Diagnostics, Biocine (a joint venture with Chiron in the Vaccine business), and the US Generics business.

After retiring from CIBA-Geigy, John was CEO of Covance Biotechnology Services, Inc., Research Triangle Park, NC, a contract manufacturer of Biopharma active ingredients (later sold to AKZO NOBEL), CEO of Integrated Biosystems, Inc., Napa, CA, a manufacturer of production equipment for Bio Pharmaceutical customers (e.g., Genentech, Amgen); (later sold to Stedim, SA, France); and President of Bausch & Lomb, London, where he oversaw Europe, Middle East & Africa. John had charge of the entire portfolio of eye care products (Surgical, Pharma, and Vision Care), representing around $2.5B in sales.

read more